KRAS and cancer: Differential immunogenicity analysis (that is, comparing the predicted immunogenicity of driver gene mutations in cancers with those mutations versus those without those mutations) identified five driver genes (BRAF, TP53, SMAD4, PIK3CA and KRAS) that had significantly higher mutation frequencies (PBonferroni < 0.1; Wilcoxon rank-sum test) in patients in whom their immunogenicity was predicted to be lower (Fig. 3f).